Analysis of gut microbiota in rheumatoid arthritis patients: Disease-related dysbiosis and modifications induced by etanercept

Andrea Picchianti-Diamanti, Concetta Panebianco, Simonetta Salemi, Maria Laura Sorgi, Roberta Di Rosa, Alessandro Tropea, Mayla Sgrulletti, Gerardo Salerno, Fulvia Terracciano, Raffaele D’amelio, Bruno Laganà, Valerio Pazienza

Research output: Contribution to journalArticle

Abstract

A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.

Original languageEnglish
Article number2938
JournalInternational Journal of Molecular Sciences
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Dysbiosis
arthritis
Rheumatoid Arthritis
amsonic acid
Microbiota
Chemical analysis
Patient treatment
Rheumatoid Factor
Immunosuppressive Agents
Sedimentation
Methotrexate
C-Reactive Protein
Euryarchaeota
Restoration
Tumor Necrosis Factor-alpha
necrosis
Blood Sedimentation
habits
Proteins
abnormalities

Keywords

  • Anti-TNF-α
  • Disease activity
  • Etanercept
  • Methotrexate
  • Microbiota
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Analysis of gut microbiota in rheumatoid arthritis patients : Disease-related dysbiosis and modifications induced by etanercept. / Picchianti-Diamanti, Andrea; Panebianco, Concetta; Salemi, Simonetta; Sorgi, Maria Laura; Di Rosa, Roberta; Tropea, Alessandro; Sgrulletti, Mayla; Salerno, Gerardo; Terracciano, Fulvia; D’amelio, Raffaele; Laganà, Bruno; Pazienza, Valerio.

In: International Journal of Molecular Sciences, Vol. 19, No. 10, 2938, 01.10.2018.

Research output: Contribution to journalArticle

Picchianti-Diamanti, Andrea ; Panebianco, Concetta ; Salemi, Simonetta ; Sorgi, Maria Laura ; Di Rosa, Roberta ; Tropea, Alessandro ; Sgrulletti, Mayla ; Salerno, Gerardo ; Terracciano, Fulvia ; D’amelio, Raffaele ; Laganà, Bruno ; Pazienza, Valerio. / Analysis of gut microbiota in rheumatoid arthritis patients : Disease-related dysbiosis and modifications induced by etanercept. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 10.
@article{f9af64bc97b8411bb09afe3186620c25,
title = "Analysis of gut microbiota in rheumatoid arthritis patients: Disease-related dysbiosis and modifications induced by etanercept",
abstract = "A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-na{\"i}ve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.",
keywords = "Anti-TNF-α, Disease activity, Etanercept, Methotrexate, Microbiota, Rheumatoid arthritis",
author = "Andrea Picchianti-Diamanti and Concetta Panebianco and Simonetta Salemi and Sorgi, {Maria Laura} and {Di Rosa}, Roberta and Alessandro Tropea and Mayla Sgrulletti and Gerardo Salerno and Fulvia Terracciano and Raffaele D’amelio and Bruno Lagan{\`a} and Valerio Pazienza",
year = "2018",
month = "10",
day = "1",
doi = "10.3390/ijms19102938",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Analysis of gut microbiota in rheumatoid arthritis patients

T2 - Disease-related dysbiosis and modifications induced by etanercept

AU - Picchianti-Diamanti, Andrea

AU - Panebianco, Concetta

AU - Salemi, Simonetta

AU - Sorgi, Maria Laura

AU - Di Rosa, Roberta

AU - Tropea, Alessandro

AU - Sgrulletti, Mayla

AU - Salerno, Gerardo

AU - Terracciano, Fulvia

AU - D’amelio, Raffaele

AU - Laganà, Bruno

AU - Pazienza, Valerio

PY - 2018/10/1

Y1 - 2018/10/1

N2 - A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.

AB - A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.

KW - Anti-TNF-α

KW - Disease activity

KW - Etanercept

KW - Methotrexate

KW - Microbiota

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85054496085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054496085&partnerID=8YFLogxK

U2 - 10.3390/ijms19102938

DO - 10.3390/ijms19102938

M3 - Article

C2 - 30261687

AN - SCOPUS:85054496085

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 10

M1 - 2938

ER -